Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Large Employer Drug Contracting Block Could Challenge Manufacturers, PBMs

Executive Summary

Express Scripts has been talking to members of the Health Transformation Alliance about negotiating pricing on behalf of the group, which includes 20 large employers providing health benefits for four million individuals.

You may also be interested in...



Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017

Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.

Employer Insurance Alliance May Test New PBM Contracting Approaches

Pilot project will launch in 2017, aiming to share data and best practices to control health care costs and create better outcomes.

CVS Continues Preferred Status For Harvoni Over Viekira Pak

With the release of its formulary exclusions for 2016, CVS Health continues to prefer Gilead's HCV treatment over AbbVie's; just last week, Express Scripts continued with the opposite.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS118843

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel